{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T07:02:27Z","timestamp":1767769347448,"version":"3.48.0"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Preclinical and clinical evidence suggested the potential benefits of treatment with acetylsalicylic acid (ASA) in mitigating COVID-19 severity. While available studies largely focused on the intracellular pathways through which ASA impairs viral replication or dampens host immunoresponse stimulated by SARS-CoV-2, whether ASA directly affects the interaction between the viral spike protein and its cellular receptor angiotensin converting enzyme 2 (ACE2) remains unexplored. This question is clinically relevant, as circulating spike S1 has been shown to persist in patients with acute and long COVID-19, where its interaction with the broadly expressed ACE2 drives systemic manifestations and tissue damage. Here, we demonstrate that pre-incubation of the SARS-CoV-2 spike subunit 1 (S1) with ASA dose-dependently impaired ACE2 binding on Vero cells. The functional relevance of this finding was confirmed in transgenic mice with human ACE2, in which intratracheal administration of ASA-treated S1 markedly reduced lung injury, fibrosis, and inflammation compared to untreated S1. Glycoproteomic profiling revealed that ASA altered the glycosylation landscape of S1, particularly N-glycosylation at N61 and O-glycosylation at S325. Site-directed mutagenesis of these two residues confirmed the critical role of their glycosylation in S1-ACE2 binding\n                    <jats:italic>in vitro<\/jats:italic>\n                    . Consistently, the glycosylation-insensitive S1 had limited effect in inducing lung injury, fibrosis, and inflammation in transgenic mice compared to WT S1, phenocopying the protective effects of ASA. These findings unveil a previously unrecognized antiviral activity of ASA, providing a molecular rationale for its repurposing as a low-cost, readily available intervention to prevent the progression from mild to severe COVID-19.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1706997","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:59:07Z","timestamp":1767769147000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Acetylsalicylic acid disrupts SARS-CoV-2 spike protein glycosylation and selectively impairs binding to ACE2"],"prefix":"10.3389","volume":"16","author":[{"given":"Luca","family":"Perico","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Bovio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Tomasoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piera","family":"Trionfini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Cerullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Corna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Pezzotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Alberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariela","family":"Benigni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30243-7","article-title":"Estimates of the severity of coronavirus disease 2019: a model-based analysis","volume":"20","author":"Verity","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138070","article-title":"Clinical and pathological investigation of patients with severe COVID-19","volume":"5","author":"Li","year":"2020","journal-title":"JCI Insight"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00536-9","article-title":"Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19","volume":"21","author":"Bonaventura","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00762-9","article-title":"Understanding COVID-19-associated coagulopathy","volume":"22","author":"Conway","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2021.1874231","article-title":"Role of endothelial cell receptors in the context of SARS-CoV-2 infection (COVID-19)","volume":"34","author":"Zhang","year":"2021","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-021-00665-7","article-title":"Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium","volume":"19","author":"Gorog","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41569-020-00469-1","article-title":"Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation","volume":"18","author":"Gu","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-020-00243-2","article-title":"COVID-19: immunopathogenesis and immunotherapeutics","volume":"5","author":"Yang","year":"2020","journal-title":"Sig Transduct Target Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41392-020-0191-1","article-title":"Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2","volume":"5","author":"Catanzaro","year":"2020","journal-title":"Sig Transduct Target Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-022-01015-x","article-title":"Immune response in COVID-19: what is next","volume":"29","author":"Li","year":"2022","journal-title":"Cell Death Differ"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000001024","article-title":"NSAIDs for early management of acute respiratory infections","volume":"37","author":"Bassetti","year":"2024","journal-title":"Curr Opin Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00433-9","article-title":"Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents","volume":"23","author":"Perico","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100941","article-title":"A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study","volume":"37","author":"Suter","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.785785","article-title":"A home-treatment algorithm based on anti-inflammatory drugs to prevent hospitalization of patients with early COVID-19: A matched-cohort study (COVER 2)","volume":"9","author":"Consolaro","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26102","article-title":"Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis","volume":"96","author":"Meizlish","year":"2021","journal-title":"Am J Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27053","article-title":"Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19","volume":"93","author":"Haji Aghajani","year":"2021","journal-title":"J Med Virol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000005292","article-title":"Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019","volume":"132","author":"Chow","year":"2021","journal-title":"Anesth Analg"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16198","article-title":"Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease","volume":"25","author":"Yuan","year":"2021","journal-title":"J Cell Mol Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15784","article-title":"The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection","volume":"288","author":"Merzon","year":"2021","journal-title":"FEBS J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.thromres.2020.04.024","article-title":"Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy","volume":"191","author":"Lodigiani","year":"2020","journal-title":"Thromb Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1620\/tjem.252.73","article-title":"Mortality risk factors among hospitalized COVID-19 patients in a major referral center in Iran","volume":"252","author":"Alamdari","year":"2020","journal-title":"Tohoku J Exp Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e14515","DOI":"10.1111\/ijcp.14515","article-title":"Use of aspirin in reduction of mortality of COVID-19 patients: A meta-analysis","volume":"75","author":"Srivastava","year":"2021","journal-title":"Int J Clin Pract"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e223890","DOI":"10.1001\/jamanetworkopen.2022.3890","article-title":"Association of early aspirin use with in-hospital mortality in patients with moderate COVID-19","volume":"5","author":"Chow","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-022-03356-5","article-title":"Does aspirin have an effect on risk of death in patients with COVID-19? A meta-analysis","volume":"78","author":"Ma","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0246825","DOI":"10.1371\/journal.pone.0246825","article-title":"Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration","volume":"16","author":"Osborne","year":"2021","journal-title":"PLoS One"},{"key":"B27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ijid.2021.05.016","article-title":"Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimates","volume":"108","author":"Martha","year":"2021","journal-title":"Int J Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cegh.2021.100883","article-title":"The effects of aspirin on the outcome of COVID-19: A systematic review and meta-analysis","volume":"12","author":"Wijaya","year":"2021","journal-title":"Clin Epidemiol Glob Health"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e24544","DOI":"10.1097\/MD.0000000000024544","article-title":"Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19","volume":"100","author":"Liu","year":"2021","journal-title":"Med (Baltimore)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e024530","DOI":"10.1161\/JAHA.121.024530","article-title":"Aspirin therapy on prophylactic anticoagulation for patients hospitalized with COVID-19: A propensity score-matched cohort analysis of the HOPE-COVID-19 registry","volume":"11","author":"Santoro","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2021-319552","article-title":"Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry","volume":"108","author":"Santoro","year":"2022","journal-title":"Heart"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01825-0","article-title":"Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00299-5","article-title":"Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial","volume":"10","author":"Eikelboom","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03943.x","article-title":"Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy","volume":"72","author":"Warner","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/fmch-2020-000741","article-title":"Rationales and uncertainties for aspirin use in COVID-19: a narrative review","volume":"9","author":"Ahmed","year":"2021","journal-title":"Fam Med Com Health"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22215","article-title":"Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways","volume":"47","author":"Trujillo-Murillo","year":"2008","journal-title":"Hepatology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)31313-4","article-title":"Use of proteomic analysis tools to identify HCV-proteins down-regulated by acetylsalicylic acid","volume":"12","author":"S\u00e1nchez-Garc\u00eda","year":"2013","journal-title":"Ann Hepatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12446","article-title":"Aspirin inhibits hepatitis C virus entry by downregulating claudin-1","volume":"23","author":"Yin","year":"2016","journal-title":"J Viral Hepat"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.75.17.7828-7839.2001","article-title":"Salicylates inhibit flavivirus replication independently of blocking nuclear factor kappa B activation","volume":"75","author":"Liao","year":"2001","journal-title":"J Virol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12985-023-02199-5","article-title":"Aspirin inhibits rotavirus replication and alters rat gut microbial composition","volume":"20","author":"Zhao","year":"2023","journal-title":"Virol J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/irv.12421","article-title":"Antiviral activity of aspirin against RNA viruses of the respiratory tract-an in vitro study","volume":"11","author":"Glatthaar-Saalm\u00fcller","year":"2017","journal-title":"Influenza Other Respir Viruses"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1462-5822.2007.00902.x","article-title":"Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity","volume":"9","author":"Mazur","year":"2007","journal-title":"Cell Microbiol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1056\/nejm198809223191218","article-title":"Anti-influenza viral activity of aspirin in cell culture","volume":"319","author":"Huang","year":"1988","journal-title":"N Engl J Med"},{"key":"B44","first-page":"397","article-title":"In vitro activity of acetylsalicylic acid on replication of varicella-zoster virus","volume":"21","author":"Primache","year":"1998","journal-title":"New Microbiol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.81.16.5223","article-title":"Dose-related effect of acetylsalicylic acid on replication of varicella zoster virus","volume":"81","author":"Walz-Cicconi","year":"1984","journal-title":"vitro. Proc Natl Acad Sci U.S.A"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1161\/01.res.83.2.210","article-title":"Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells","volume":"83","author":"Speir","year":"1998","journal-title":"Circ Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10101619","article-title":"Acetylsalicylic acid and salicylic acid inhibit SARS-CoV-2 replication in precision-cut lung slices","volume":"10","author":"Geiger","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00211-1","article-title":"Plasma-based antigen persistence in the post-acute phase of COVID-19","volume":"24","author":"Peluso","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.09.001","article-title":"Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study","volume":"30","author":"Swank","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e28568","DOI":"10.1002\/jmv.28568","article-title":"Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19","volume":"95","author":"Craddock","year":"2023","journal-title":"J Med Virol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac722","article-title":"Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae","volume":"76","author":"Swank","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.chom.2024.11.007","article-title":"Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19","volume":"32","author":"Rong","year":"2024","journal-title":"Cell Host Microbe"},{"key":"B53","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.tim.2023.06.004","article-title":"SARS-CoV-2 and the spike protein in endotheliopathy","volume":"32","author":"Perico","year":"2024","journal-title":"Trends Microbiol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41392-020-00454-7","article-title":"Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches","volume":"5","author":"Jin","year":"2020","journal-title":"Sig Transduct Target Ther"},{"key":"B55","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41581-020-00357-4","article-title":"Immunity, endothelial injury and complement-induced coagulopathy in COVID-19","volume":"17","author":"Perico","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000692","article-title":"Angiotensin-converting enzyme 2: from a vasoactive peptide to the gatekeeper of a global pandemic","volume":"30","author":"Perico","year":"2021","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1159\/000507305","article-title":"Should COVID-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade","volume":"144","author":"Perico","year":"2020","journal-title":"Nephron"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S47895","article-title":"Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers","volume":"6","author":"Nagelschmitz","year":"2014","journal-title":"Clin Pharmacol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2\u2013spike protein\u2013protein interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e0214725","DOI":"10.1371\/journal.pone.0214725","article-title":"Prevention of haemoglobin glycation by acetylsalicylic acid (ASA): A new view on old mechanism","volume":"14","author":"Ghazanfari-Sarabi","year":"2019","journal-title":"PLoS One"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.cdev.2024.203941","article-title":"Identification of a fibronectin-binding protein signature associated with idiopathic pulmonary fibrosis","volume":"179","author":"Sun","year":"2024","journal-title":"Cells Dev"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1068449","article-title":"Protein post-translational modification in SARS-CoV-2 and host interaction","volume":"13","author":"Cheng","year":"2023","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41392-021-00809-8","article-title":"The glycosylation in SARS-CoV-2 and its receptor ACE2","volume":"6","author":"Gong","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/s41467-023-36745-0","article-title":"Structural dynamics in the evolution of SARS-CoV-2 spike glycoprotein","volume":"14","author":"Calvaresi","year":"2023","journal-title":"Nat Commun"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.0c01056","article-title":"Beyond shielding: the roles of glycans in the SARS-CoV-2 spike protein","volume":"6","author":"Casalino","year":"2020","journal-title":"ACS Cent Sci"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1071\/MA24005","article-title":"Cellular signalling by SARS-CoV-2 spike protein","volume":"45","author":"Gracie","year":"2024","journal-title":"Microbiol Aust"},{"key":"B67","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12931-025-03143-7","article-title":"Acute lung injury induced by recombinant SARS-CoV-2 spike protein subunit S1 in mice","volume":"26","author":"Zhu","year":"2025","journal-title":"Respir Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.01.039","article-title":"Angiotensin-converting enzyme 2\u2014at the heart of the COVID-19 pandemic","volume":"186","author":"Oudit","year":"2023","journal-title":"Cell"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb9983","article-title":"Site-specific glycan analysis of the SARS-CoV-2 spike","volume":"369","author":"Watanabe","year":"2020","journal-title":"Science"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.0c03173","article-title":"and O-glycosylation of the SARS-CoV-2 spike protein","volume":"93","author":"Sanda","year":"2021","journal-title":"Anal Chem"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.1c01785","article-title":"Impact of expressing cells on glycosylation and glycan of the SARS-CoV-2 spike glycoprotein","volume":"6","author":"Wang","year":"2021","journal-title":"ACS Omega"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-0485-4","article-title":"Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19","volume":"41","author":"Huang","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/v13040551","article-title":"Site-specific O-glycosylation analysis of SARS-CoV-2 spike protein produced in insect and human cells","volume":"13","author":"Bagdonaite","year":"2021","journal-title":"Viruses"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-021-00545-2","article-title":"O-glycosylation pattern of the SARS-CoV-2 spike protein reveals an \u201cO-Follow-N\u201d rule","volume":"31","author":"Tian","year":"2021","journal-title":"Cell Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwaa042","article-title":"Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2","volume":"30","author":"Shajahan","year":"2020","journal-title":"Glycobiology"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2021.767448","article-title":"Site-specific glycosylation patterns of the SARS-CoV-2 spike protein derived from recombinant protein and viral WA1 and D614G strains","volume":"9","author":"Tian","year":"2021","journal-title":"Front Chem"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e61552","DOI":"10.7554\/eLife.61552","article-title":"Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration","volume":"9","author":"Yang","year":"2020","journal-title":"Elife"},{"key":"B78","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.chom.2020.08.004","article-title":"Virus-receptor interactions of glycosylated SARS-CoV-2 spike and human ACE2 receptor","volume":"28","author":"Zhao","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.0c03301","article-title":"Comprehensive analysis of the glycan complement of SARS-coV-2 spike proteins using signature ions-triggered electron-transfer\/higher-energy collisional dissociation (EThcD) mass spectrometry","volume":"92","author":"Wang","year":"2020","journal-title":"Anal Chem"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.0c04634","article-title":"Comprehensive O-glycosylation analysis of the SARS-CoV-2 spike protein with biomimetic trp-arg materials","volume":"93","author":"Dong","year":"2021","journal-title":"Anal Chem"},{"key":"B82","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41589-021-00924-1","article-title":"Sialic acid-containing glycolipids mediate binding and viral entry of SARS-CoV-2","volume":"18","author":"Nguyen","year":"2022","journal-title":"Nat Chem Biol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"100058","DOI":"10.1074\/mcp.RA120.002295","article-title":"Site-specific N-glycosylation characterization of recombinant SARS-CoV-2 spike proteins","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol Cell Proteomics"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwaa085","article-title":"Site-specific characterization of SARS-CoV-2 spike glycoprotein receptor-binding domain","volume":"31","author":"Antonopoulos","year":"2021","journal-title":"Glycobiology"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01672-23","article-title":"SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity","volume":"15","author":"Zhang","year":"2024","journal-title":"mBio"},{"key":"B86","article-title":"Non-enzymatic acetylation of proteins by aspirin as protection against the secondary complications of diabetes mellitus","volume":"36","author":"Hun-Opfer","year":"1986","journal-title":"Acta Physiol Pharmacol Latinoam"},{"key":"B87","doi-asserted-by":"publisher","first-page":"113444","DOI":"10.1016\/j.celrep.2023.113444","article-title":"Evolution of the SARS-CoV-2 omicron spike","volume":"42","author":"Parsons","year":"2023","journal-title":"Cell Rep"},{"key":"B88","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41392-022-00992-2","article-title":"Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events","volume":"7","author":"Ou","year":"2022","journal-title":"Sig Transduct Target Ther"},{"key":"B89","doi-asserted-by":"publisher","first-page":"10053","DOI":"10.1038\/s41598-023-33088-0","article-title":"Site specific N- and O-glycosylation mapping of the spike proteins of SARS-CoV-2 variants of concern","volume":"13","author":"Shajahan","year":"2023","journal-title":"Sci Rep"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1617174114","article-title":"Influenza A surface glycosylation and vaccine design","volume":"114","author":"Wu","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e1006796","DOI":"10.1371\/journal.ppat.1006796","article-title":"Influenza A virus hemagglutinin glycosylation compensates for antibody escape fitness costs","volume":"14","author":"Kosik","year":"2018","journal-title":"PLoS Pathog"},{"key":"B92","doi-asserted-by":"publisher","first-page":"11392","DOI":"10.1038\/s41598-023-38382-5","article-title":"SARS-CoV-2 spike protein induces lung endothelial cell dysfunction and thrombo-inflammation depending on the C3a\/C3a receptor signalling","volume":"13","author":"Perico","year":"2023","journal-title":"Sci Rep"},{"key":"B93","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s13287-025-04472-6","article-title":"Mesenchymal stromal cell secretome reduces lung injury and thrombo-inflammation induced by SARS-CoV-2 spike protein","volume":"16","author":"Pezzotta","year":"2025","journal-title":"Stem Cell Res Ther"},{"key":"B94","doi-asserted-by":"publisher","first-page":"e3000411","DOI":"10.1371\/journal.pbio.3000411","article-title":"Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"103069","DOI":"10.1016\/j.ebiom.2020.103069","article-title":"COVID-19 and lombardy: TESTing the impact of the first wave of the pandemic","volume":"61","author":"Perico","year":"2020","journal-title":"EBioMedicine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1706997\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:59:12Z","timestamp":1767769152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1706997\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":95,"alternative-id":["10.3389\/fimmu.2025.1706997"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1706997","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"article-number":"1706997"}}